Home › Acute Lymphoblastic Leukemia › New Mexico › Albuquerque
Acute Lymphoblastic Leukemia clinical trials in Albuquerque, NM
3 studies for Acute Lymphoblastic Leukemia are looking for participants at sites in and around Albuquerque (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- and 1 more
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- University of New Mexico Cancer Center, Albuquerque
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RecruitingObservational study
- University of New Mexico Cancer Center, Albuquerque
Acute Lymphoblastic Leukemia trials in other cities
- Houston, TX28 studies
- New York City, NY24 studies
- Baldwin Park, CA21 studies
- Seattle, WA21 studies
- Atlanta, GA19 studies
- Chicago, IL19 studies
- Memphis, TN16 studies
- Philadelphia, PA16 studies
- Washington, DC16 studies
- Boston, MA15 studies
- Los Angeles, CA14 studies
- Durham, NC13 studies
Other studies in Albuquerque
- Non-Small Cell Lung Cancer18 studies
- Breast Cancer17 studies
- Ovarian Cancer15 studies
- Lung Cancer14 studies
- Cancer (all types)14 studies
- Endometrial Cancer12 studies
- Metastatic Cancer12 studies
- Type 2 Diabetes11 studies
- Cardiovascular Disease10 studies
- Prostate Cancer9 studies
- Melanoma9 studies
- Acute Myeloid Leukemia9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.